| 标题 |
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study |
| 网址 | |
| DOI | |
| 其它 |
期刊:The Lancet 作者:Meletios Α. Dimopoulos; Hang Quach; María‐Victoria Mateos; Ola Landgren; Xavier Leleu; et al 出版日期:2020-07-01 |
| 求助人 | |
| 下载 | 求助已完成,仅限求助人下载。 |
PDF的下载单位、IP信息已删除
(2025-6-4)